Table 2.
Clinical features, laboratory indexes and the use of medicines in SLE and RA patients.
| Parameters | SLE (n = 60) | RA (n = 70) |
|---|---|---|
| Disease duration (years) | 5.0 [2,8] | 6.0 [2,10] |
| ESR (mm/h) | 19 [10,24] | 20.07 ± 16.68 |
| CRP (g/L) | 3.13 (0.86, 6.16) | 3.13 (1.04, 5.99) |
| C3 (g/L) | 0.84 ± 0.26 | 0.67 ± 0.23 |
| C4 (g/L) | 0.15 ± 0.79 | 0.16 ± 0.45 |
| Serum IgA (g/L) | 3.03 ± 0.97 | 2.92 ± 0.67 |
| Serum IgM (g/L) | 1.13 ± 0.69 | 1.06 ± 0.53 |
| Serum IgG (g/L) | 14.83 ± 4.70 | 12.16 ± 2.89 |
| Disease activity score | 2.30 ± 3.68 (SLEDAI) | 3.71 ± 2.09 (DAS28) |
| Disease manifestations (n/ (%)) | ||
| Renal disease | 18 (30.0) | – |
| Vasculitis | 4 (6.7) | – |
| Arthritis | 6 (10.0) | – |
| Myositis | 5 (8.3) | – |
| Rash | 6 (10.0) | – |
| Alopecia | 5 (8.3) | – |
| Oral ulcer | 4 (6.7) | – |
| Pericarditis | 5 (8.3) | – |
| Pleuritis | 0 (0) | – |
| Leukopenia | 7 (11.7) | – |
| Thrombocytopenia | 6 (10.0) | – |
| Nervous system disorder | 1 (1.7) | – |
| Low complement | 1 (1.7) | – |
| Comorbidities (n/ (%)) | ||
| Morning stiffness | – | 4 (5.7) |
| Diabetes | 4 (6.7) | 2 (2.9) |
| Hypertension | 13 (21.7) | 3 (4.3) |
| Interstitial pneumonia | 5 (8.3) | 3 (4.3) |
| Autoantibodies | ||
| Anti-CCP (+/-) | – | 30/40 |
| AKA (+/-) | – | 14/56 |
| RF (+/-) | – | 37/33 |
| Anti-dsDNA (+/-) | 5/55 | – |
| Anti-Sm 18 (+/-) | 6/54 | – |
| Anti-SSA (+/-) | 11/49 | – |
| Anti-SSB (+/-) | 9/51 | – |
| Anti-RNP (+/-) | 3/57 | – |
| Anti-Ribosomal P (+/-) | 3/57 | – |
| Medical therapy | ||
| Prednisone (n/ (%)) | 55 (91.7) | 27 (38.6) |
| Dose (mg) | 8.62 ± 8.82 | 6.41 ± 2.92 |
| Hydroxychloroquine (n/ (%)) | 56 (93.3) | 26 (37.1) |
| Dose (mg) | 226.78 ± 48.58 | 230.77 ± 47.07 |
| Methotrexate (n/ (%)) | 8 (13.3) | 40 (57.1) |
| Dose (mg) | 10.25 ± 0.71 | 15.38 ± 4.92 |
| Ciclosporin (n/ (%)) | 11 (18.3) | – |
| Dose (mg) | 114.28 ± 62.68 | – |
| Leflunomide (n/ (%)) | 4 (6.7) | 39 (55.7) |
| Dose (mg) | 8.75 ± 2.50 | 10.28 ± 2.32 |
| Other Medications | ||
| Alfacalcidol (n/ (%)) | 4 (6.7) | 11 (15.7) |
| Dose (ug) | 0.38 ± 0.14 | 0.43 ± 0.12 |
| Rabeprazole (n/ (%)) | 3 (5.0) | – |
| Dose (mg) | 17.50 ± 5.00 | – |
| Aspirin (n/ (%)) | 4 (6.7) | – |
| Dose (mg) | 100 | – |
| Iguratimod (n/ (%)) | – | 4 (5.7) |
| Dose (mg) | – | 25 |
| Total glucosides of paeony (n/ (%)) | – | 5 (7.1) |
| Dose (g) | – | 0.78 ± 0.18 |
SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SLEDAI: SLE disease activity index; DAS28: the disease activity score using 28 joint counts